TLT — Theralase Technologies Share Price
0.000.00%
Last trade - 00:00- CA$40.68m
- CA$40.59m
- CA$1.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 24.54 | ||
| Price to Tang. Book | 24.54 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 44.19 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -231.71% | ||
| Return on Equity | -238.55% | ||
| Operating Margin | -478.72% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.96 | 0.93 | 0.78 | 1.14 | 1.07 | 0.53 | 1.5 | -9.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.
Directors
- Matthew Perraton NEC
- Arkady Mandel CEO
- Shawn Shirazi CEO
- Kristina Hachey CFO
- Guy Anderson IND
- Randall Bruder IND
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- August 22nd, 1989
- Public Since
- November 2nd, 2004
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 239,295,306
- Address
- 41 Hollinger Road, TORONTO, M4B 3G4
- Web
- https://theralase.com/
- Phone
- +1 4166995273
- Contact
- Kristina Hachey
- Auditors
- AGT Partners LLP
Upcoming Events for TLT
Similar to TLT
Aurora Spine
TSX Venture Exchange
CardioComm Solutions
TSX Venture Exchange
Enablence Technologies
TSX Venture Exchange
EvokAI Creative Labs
TSX Venture Exchange
Evome Medical Technologies
TSX Venture Exchange
FAQ
What is the Theralase Technologies share price?
As of Today at 24:08 UTC, shares in Theralase Technologies are trading at CA$0.17. This share price information is delayed by 15 minutes.
How has the Theralase Technologies share price performed this year?
Shares in Theralase Technologies last closed at CA$0.17 and the price had moved by -30.61% over the past 365 days. In terms of relative price strength the Theralase Technologies share price has underperformed the Toronto Stock Exchange 300 Composite Index by -39.29% over the past year.
What are the analyst and broker recommendations for Theralase Technologies?
The overall consensus recommendation for Theralase Technologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Theralase Technologies dividend yield?
Theralase Technologies does not currently pay a dividend.
Does Theralase Technologies pay a dividend?
Theralase Technologies does not currently pay a dividend.
When does Theralase Technologies next pay dividends?
Theralase Technologies does not currently pay a dividend.
How do I buy Theralase Technologies shares?
To buy shares in Theralase Technologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Theralase Technologies?
As of the previous close price of CA$0.17, shares in Theralase Technologies had a market capitalisation of CA$40.68m.
Where are Theralase Technologies shares listed?
Here are the trading details for Theralase Technologies:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: TLT
What kind of share is Theralase Technologies?
Based on an overall assessment of its quality, value and momentum Theralase Technologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Theralase Technologies share price forecast for 2024?
The analyst consensus target price for shares in Theralase Technologies is CA$0.80. That is 370.59% above the last closing price of CA$0.17.
Analysts covering Theralase Technologies currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.01 for the next financial year.
Find out moreWhat is the trend in the Theralase Technologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Theralase Technologies. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -24.99%.
As of the last closing price of CA$0.17, shares in Theralase Technologies were trading -5.44% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Theralase Technologies PE Ratio?
The Theralase Technologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Theralase Technologies?
Theralase Technologies' management team is headed by:
- Matthew Perraton - NEC
- Arkady Mandel - CEO
- Shawn Shirazi - CEO
- Kristina Hachey - CFO
- Guy Anderson - IND
- Randall Bruder - IND